Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting [Yahoo! Finance]
MediumReport
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting [Yahoo! Finance]
Monopar Announces CFO Succession Generative AI Software Sales Could Soar by 6,260% by 2032: 1 Unstoppable Artificial Intelligence Stock to Buy Before They Do (Hint: It's Not Nvidia) Who Owns the Most Nvidia Stock Besides CEO Jensen Huang? Billionaire Ken
LowReport
Monopar Announces CFO Succession Generative AI Software Sales Could Soar by 6,260% by 2032: 1 Unstoppable Artificial Intelligence Stock to Buy Before They Do (Hint: It's Not Nvidia) Who Owns the Most Nvidia Stock Besides CEO Jensen Huang? Billionaire Ken
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
MediumReport
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: